Compass Pathways/$CMPS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Compass Pathways
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
Ticker
$CMPS
Sector
Primary listing
Employees
156
Headquarters
Website
Compass Pathways Metrics
BasicAdvanced
$1.6bn
-
-$3.08
2.40
-
Price and volume
Market cap
$1.6bn
Beta
2.4
52-week high
$12.48
52-week low
$2.25
Average daily volume
5.7m
Financial strength
Current ratio
3.322
Quick ratio
3.128
Long term debt to equity
15.689
Total debt to equity
16.318
Interest coverage (TTM)
-35.93%
Profitability
EBITDA (TTM)
-174.316
Effective tax rate (TTM)
1.56%
Management effectiveness
Return on assets (TTM)
-25.64%
Return on equity (TTM)
-68.48%
Valuation
Price to book
5.05
Price to tangible book (TTM)
5.05
Price to free cash flow (TTM)
-7.566
Free cash flow yield (TTM)
-13.22%
Free cash flow per share (TTM)
-1.616
Growth
Earnings per share change (TTM)
58.47%
3-year earnings per share growth (CAGR)
11.55%
What the Analysts think about Compass Pathways
Analyst ratings (Buy, Hold, Sell) for Compass Pathways stock.
Compass Pathways Financial Performance
Revenues and expenses
Compass Pathways Earnings Performance
Company profitability
Compass Pathways News
AllArticlesVideos
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins
MarketBeat·6 days ago
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
Business Wire·2 weeks ago
Compass Pathways shares rise on Q1 results, accelerated FDA review
Proactive Investors·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs